Garganeeva A A, Kuzheleva E A, Tukish O V, Kondratiev M Yu, Vitt K N, Andreev S L, Ogurkova O N
Research Institute of Cardiology, Tomsk National Research Medical Center.
Kardiologiia. 2024 Feb 29;64(2):18-26. doi: 10.18087/cardio.2024.2.n2465.
To study the prognostic significance of inflammatory biomarkers in patients with chronic heart failure (CHF) and stenotic multivessel coronary atherosclerosis, with determination of the biomarker separate set that reflects subclinical inflammation and is associated with the development of cardiovascular complications during prospective observation.
A prospective observational study was conducted that included 80 patients with CHF and ischemic heart disease who were scheduled for coronary artery bypass grafting (CABG) during their current hospitalization. In addition to routine clinical laboratory tests, coagulation parameters were evaluated and the following inflammatory biomarkers were determined: neutrophil gelatinase-associated lipocalin (NGAL), growth/differentiation factor 15 (GDF-15), fibroblast growth factor 23 (FGF-23), transforming growth factor beta-1 (TGF-β1), and high-sensitivity C-reactive protein. Also, the calculated neutrophil-to-lymphocyte ratio (N LR) was included in the analysis. Follow-up duration was at least 12 months (median 16 [13, 22] months). Statistical analysis of the data was performed with the IBM SPSS Statistics 21 software.
The study presented results of a factor analysis of 10 inflammatory biomarkers in patients who were scheduled for CABG. One of the factors identified by the analysis included the levels of NGAL and GDF-15, N LR, and the level of fibrinogen in the blood in CHF patients with stenotic coronary atherosclerosis and was significantly associated with the death rate during prospective observation. Furthermore, this association remained significant even after adjustments for age, glomerular filtration rate, severity of heart and coronary insufficiency, and the presence of diabetes mellitus.
In patients with CHF and stenotic coronary atherosclerosis, a set of inflammatory markers, including blood NGAL, GDF-15, N LR, and fibrinogen, can be combined into one factor reflecting subclinical inflammation. The value of this factor can be used to predict cardiovascular death in the long term after surgical myocardial revascularization.
研究炎症生物标志物在慢性心力衰竭(CHF)合并多支冠状动脉狭窄性动脉粥样硬化患者中的预后意义,确定反映亚临床炎症且与前瞻性观察期间心血管并发症发生相关的生物标志物独立组合。
进行了一项前瞻性观察研究,纳入80例CHF和缺血性心脏病患者,他们计划在本次住院期间接受冠状动脉旁路移植术(CABG)。除常规临床实验室检查外,评估凝血参数并测定以下炎症生物标志物:中性粒细胞明胶酶相关脂质运载蛋白(NGAL)、生长/分化因子15(GDF-15)、成纤维细胞生长因子23(FGF-23)、转化生长因子β1(TGF-β1)和高敏C反应蛋白。此外,计算得出的中性粒细胞与淋巴细胞比值(N LR)也纳入分析。随访时间至少为12个月(中位数16[13,22]个月)。使用IBM SPSS Statistics 21软件对数据进行统计分析。
该研究展示了对计划接受CABG患者的10种炎症生物标志物进行因子分析的结果。分析确定的其中一个因子包括NGAL和GDF-15水平、N LR以及CHF合并冠状动脉狭窄性动脉粥样硬化患者血液中的纤维蛋白原水平,并且与前瞻性观察期间的死亡率显著相关。此外,即使在对年龄、肾小球滤过率、心脏和冠状动脉功能不全的严重程度以及糖尿病的存在进行调整后,这种关联仍然显著。
在CHF合并冠状动脉狭窄性动脉粥样硬化患者中,一组炎症标志物,包括血液中的NGAL、GDF-15、N LR和纤维蛋白原,可以合并为一个反映亚临床炎症的因子。该因子的值可用于预测外科心肌血运重建术后的长期心血管死亡。